Valuation WuXi Biologics (Cayman) Inc. OTC Markets
Stocks
WXXWY
US98260N1081
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.610 USD | -2.56% |
|
+0.13% | -4.88% |
| 02:12am | CANbridge Pharmaceuticals Enters Service Agreements With WuXi Biologics, Baheal Medical | MT |
| Jun. 05 | Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub | CI |
Company Valuation: WuXi Biologics (Cayman) Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 318,490 | 223,690 | 113,457 | 67,752 | 116,785 | 107,079 | - | - |
| Change | - | -29.77% | -49.28% | -40.28% | 72.37% | -8.31% | - | - |
| Enterprise Value (EV) 1 | 312,249 | 220,078 | 108,009 | 62,506 | 105,088 | 95,800 | 92,648 | 86,547 |
| Change | - | -29.52% | -50.92% | -42.13% | 68.13% | -8.84% | -3.29% | -6.59% |
| P/E Ratio | 97.9x | 52.4x | 34.9x | 21.2x | 24.4x | 19.5x | 16.2x | 13.4x |
| PBR | 10.3x | 6.38x | 2.9x | 1.67x | 2.2x | 1.92x | 1.69x | 1.48x |
| PEG | - | 1.7x | -1.5x | 16.32x | 0.5x | 1.4x | 0.8x | 0.7x |
| Capitalization / Revenue | 31x | 14.7x | 6.66x | 3.63x | 5.36x | 4.25x | 3.62x | 3.11x |
| EV / Revenue | 30.3x | 14.4x | 6.34x | 3.35x | 4.82x | 3.8x | 3.13x | 2.51x |
| EV / EBITDA | 68x | 32.1x | 15.4x | 7.81x | 10.7x | 9.87x | 8.04x | 6.4x |
| EV / EBIT | 93.9x | 47.8x | 25.4x | 13.2x | 15.3x | 11.9x | 9.53x | 7.5x |
| EV / FCF | -101x | -674x | 174x | 48.5x | 45.7x | 44.3x | 26.9x | 14.8x |
| FCF Yield | -0.99% | -0.15% | 0.58% | 2.06% | 2.19% | 2.26% | 3.72% | 6.77% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.77 | 1.01 | 0.77 | 0.78 | 1.16 | 1.326 | 1.601 | 1.93 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10,290 | 15,269 | 17,034 | 18,675 | 21,790 | 25,222 | 29,593 | 34,421 |
| EBITDA 1 | 4,590 | 6,857 | 6,993 | 7,999 | 9,820 | 9,711 | 11,528 | 13,525 |
| EBIT 1 | 3,327 | 4,609 | 4,253 | 4,737 | 6,852 | 8,074 | 9,721 | 11,536 |
| Net income 1 | 3,388 | 4,420 | 3,400 | 3,356 | 4,908 | 5,497 | 6,653 | 7,918 |
| Net Debt 1 | -6,241 | -3,612 | -5,448 | -5,246 | -11,697 | -11,278 | -14,431 | -20,532 |
| Reference price 2 | 75.40 | 52.94 | 26.87 | 16.50 | 28.25 | 25.90 | 25.90 | 25.90 |
| Nbr of stocks (in thousands) | 4,224,123 | 4,225,262 | 4,222,732 | 4,105,938 | 4,133,579 | 4,133,541 | - | - |
| Announcement Date | 3/22/22 | 3/22/23 | 3/26/24 | 3/25/25 | 3/24/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E Ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32x | 8.3x | 25.1x | 0.06% | 54.54B | |
| 16.43x | 4.93x | 10.71x | 1.83% | 43.86B | |
| -17.51x | 4x | -6.98x | -.--% | 22.63B | |
| -36.18x | 11.93x | -34.8x | -.--% | 20.7B | |
| 20.6x | 4.16x | 13.77x | -.--% | 14.83B | |
| 16.47x | 4.75x | 11.13x | -.--% | 13.1B | |
| -444.13x | 30.23x | -3370.59x | -.--% | 12.66B | |
| -72.96x | 7.37x | -66.11x | -.--% | 11.56B | |
| 38.53x | 14.84x | 43.58x | -.--% | 11.68B | |
| Average | -49.64x | 10.06x | -374.91x | 0.21% | 22.84B | |
| Weighted average by Cap. | -20.31x | 8.62x | -202.51x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 2269 Stock
- WXXWY Stock
- Valuation WuXi Biologics (Cayman) Inc.
Select your edition
All financial news and data tailored to specific country editions
